In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical ...

Bioanalysis is also used to monitor therapeutic responses by evaluating drug levels, biomarkers, and physiological changes ...

According to the paper by researchers at the University of Bath in the UK and Lund University in Sweden, the self-regulated ...

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...

In conclusion, I see 2025 as a year in which the patient will still be centre-stage. But, in order for that to happen ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy ...

The stake comes alongside an agreement for Vancouver, Washington-based Absci to use AMD chips and software to power its drug ...

Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...